Díaz V M, Hurtado M, Thomson T M, Reventós J, Paciucci R
Unitat de Recerca Biomèdica, Hospital Materno-Infantil, Hospitals Vall d'Hebrón, Pg Vall d'Hebrón 119-129, 08035 Barcelona, Spain.
Gut. 2004 Jul;53(7):993-1000. doi: 10.1136/gut.2003.026831.
Overexpression of tissue plasminogen activator (t-PA) in pancreatic cancer cells promotes invasion and proliferation in vitro and tumour growth and angiogenesis in vivo.
To understand the mechanisms by which t-PA favours cancer progression, we analysed the surface membrane proteins responsible for binding specifically t-PA and studied the contribution of this interaction to the t-PA promoted invasion of pancreatic cancer cells.
The ability of t-PA to activate plasmin and a fluorogenic plasmin substrate was used to analyse the nature of the binding of active t-PA to cell surfaces. Specific binding was determined in two pancreatic cancer cell lines (SK-PC-1 and PANC-1), and complex formation analysed by co-immunoprecipitation experiments and co-immunolocalisation in tumours. The functional role of the interaction was studied in Matrigel invasion assays.
t-PA bound to PANC-1 and SK-PC-1 cells in a specific and saturable manner while maintaining its activity. This binding was competitively inhibited by specific peptides interfering with the interaction of t-PA with annexin II. The t-PA/annexin II interaction on pancreatic cancer cells was also supported by co-immunoprecipitation assays using anti-t-PA antibodies and, reciprocally, with antiannexin II antibodies. In addition, confocal microscopy showed t-PA and annexin II colocalisation in tumour tissues. Finally, disruption of the t-PA/annexin II interaction by a specific hexapeptide significantly decreased the invasive capacity of SK-PC-1 cells in vitro.
t-PA specifically binds to annexin II on the extracellular membrane of pancreatic cancer cells where it activates local plasmin production and tumour cell invasion. These findings may be clinically relevant for future therapeutic strategies based on specific drugs that counteract the activity of t-PA or its receptor annexin II, or their interaction at the surface level.
组织型纤溶酶原激活剂(t-PA)在胰腺癌细胞中的过表达促进其体外侵袭和增殖以及体内肿瘤生长和血管生成。
为了解t-PA促进癌症进展的机制,我们分析了负责特异性结合t-PA的表面膜蛋白,并研究了这种相互作用对t-PA促进胰腺癌细胞侵袭的作用。
利用t-PA激活纤溶酶和荧光纤溶酶底物的能力来分析活性t-PA与细胞表面结合的性质。在两种胰腺癌细胞系(SK-PC-1和PANC-1)中测定特异性结合,并通过共免疫沉淀实验和肿瘤中的共免疫定位分析复合物形成。在基质胶侵袭试验中研究这种相互作用的功能作用。
t-PA以特异性和可饱和的方式与PANC-1和SK-PC-1细胞结合,同时保持其活性。这种结合被干扰t-PA与膜联蛋白II相互作用的特异性肽竞争性抑制。使用抗t-PA抗体的共免疫沉淀试验以及使用抗膜联蛋白II抗体的反向试验也支持胰腺癌细胞上的t-PA/膜联蛋白II相互作用。此外,共聚焦显微镜显示t-PA和膜联蛋白II在肿瘤组织中共定位。最后,一种特异性六肽破坏t-PA/膜联蛋白II相互作用显著降低了SK-PC-1细胞在体外的侵袭能力。
t-PA特异性结合胰腺癌细胞细胞外膜上的膜联蛋白II,在那里它激活局部纤溶酶产生和肿瘤细胞侵袭。这些发现可能与未来基于特异性药物的治疗策略在临床上相关,这些药物可抵消t-PA或其受体膜联蛋白II的活性,或它们在表面水平的相互作用。